Abstracts Archive - Page 615 of 2607 - ACR Meeting Abstracts

Abstract Number: 1980 • ACR Convergence 2022
Seroconversion After a Third COVID-19 Vaccination in Rheumatoid Arthritis Patients Treated with (ultra-)low Dose Rituximab with a Previous Insufficient Humoral Response Is Associated with Rituximab Dosage
Céleste van der Togt¹, David Ten Cate¹, Janette Rahamat-Langendoen², Bart van den Bemt³, Nathan den Broeder⁴ and Alfons den Broeder⁴, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²ErasmusMC, Rotterdam, Zuid-Holland, Netherlands, ³Department of Pharmacy, Sint Maartenskliniek, Ubbergen, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Around 60% of rheumatoid arthritis (RA) patients treated with ≥1000 mg rituximab (RTX) has an insufficient deemed humoral response after two COVID-19 vaccinations. Recent…
Abstract Number: 1990 • ACR Convergence 2022
Artificial Intelligence Applied to Transcriptomics Profiling of Synovial Tissue Biopsies Accurately Predicts Rheumatoid Arthritis Patients Who Will Respond or Be Refractory to Standard Biological Treatments
Giorgio CASABURI, Todd Holscher and Ming-Chou Lee, Exagen, Inc., Vista, CA
Background/Purpose: In recent years, biological therapies have revolutionized treatments of Rheumatoid Arthritis (RA). However, about 40% of RA patients do not respond to given biologics…
Abstract Number: 1993 • ACR Convergence 2022
Changes in Omega-6- and Omega-3-Derived Bioactive Lipids in Response to an Anti-Inflammatory Dietary Intervention
Esha Lal¹, Marta Sala Climent², francesca cedola², Marta Fernandez-Bustamante³, Meritxell Agustín-Perez², Maram Alharti², Abha Singh⁴, Soo-In Choi², Tania Rivera², Katherine Nguyen⁴, Susan Lee², Aaron Armando⁵, Tiffany Holt⁶, Oswald Quehenberger⁵, Shahrokh Golshan⁶, Roxana Coras⁷ and Monica Guma⁸, ¹Department of Medicine, School of Medicine, University of California, San Diego, San Diego, ²Department of Medicine, School of Medicine, University of California, San Diego, San Diego, CA, ³Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, ⁴University of California, San Diego, San Diego, CA, ⁵Department of Pharmacology, School of Medicine, University of California, San Diego, San Diego, CA, ⁶Department of Psychiatry, School of Medicine, University of California, San Diego, San Diego, CA, ⁷University of California San Diego, San Diego, CA, ⁸UCSD, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that causes joint pain, swelling, stiffness, and decreased mobility. Despite the various treatment options for RA, many…
Abstract Number: 1926 • ACR Convergence 2022
Analysis of New Patient Referrals to a Large Pediatric Rheumatology Clinic
Daniel Reiff, Melissa Mannion, Emily Smitherman, Matthew Stoll, Peter Weiser and Randy Cron, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Large pediatric rheumatology centers receive hundreds of yearly referrals with a wide variety of complaints and diagnoses. The amount of referrals received can lead…
Abstract Number: 1983 • ACR Convergence 2022
Anti-S1 Antibody Levels Two Weeks After the Second Dose of an mRNA anti-SARS-CoV2 Vaccine Predict Maintenance of a Potent Neutralizing Activity over 24 Weeks in RA Patients
Kristin Schmiedeberg¹, Irene Abela², Nicolas Vuilleumier³, Johannes von Kempis⁴ and Andrea Rubbert-Roth⁵, ¹Cantonal Hospital St Gallen, St.Gallen, Switzerland, ²Institute of Medical Virology, University of Zurich, Zürich, Switzerland, ³Laboratory Medicine Division, Geneva University Hospitals, Geneva, Switzerland, ⁴Division of Rheumatology, Cantonal Hospital St.Gallen, St. Gallen, Switzerland, ⁵Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland
Background/Purpose: Patients with inflammatory rheumatic diseases (IRD) on immunomodulatory therapies have a higher likelihood of an impaired vaccine-induced immune response following an mRNA anti-SARS-CoV-2 vaccine.…
Abstract Number: 1987 • ACR Convergence 2022
Prednisone Use and the Incidence of Hyperglycemia or Diabetes in Patients with Rheumatoid Arthritis; A 10-year Sub Analysis of the BeSt Study
CF Allaart¹, Sytske Anne Bergstra², Tom Huizinga¹ and Joy van der Pol³, ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³Leiden University Medical Center, Utrecht, Netherlands
Background/Purpose: Use of prednisone in rheumatoid arthritis has been questioned because it may trigger side effects such as hyperglycemia and diabetes. However, disease activity (DAS)…
Abstract Number: 1998 • ACR Convergence 2022
Effect of a Lifestyle Program Based on a Whole Food Plant-based Diet, Physical Activity, and Stress Management in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial
Wendy Walrabenstein¹, Carlijn Wagenaar¹, Marike van der Leeden², Franktien Turkstra¹, Jos Twisk³, Maarten Boers⁴, Henriët van Middendorp⁵, Peter Weijs² and Dirkjan van Schaardenburg², ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Department of Epidemiology and Biostatistics, Amsterdam, Netherlands, ⁴Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁵Leiden University, Leiden, Netherlands
Background/Purpose: Lifestyle factors have been associated with the development and progression of rheumatoid arthritis. Interventions involving whole food plant-based diets (1-3), physical activity (4) or…
Abstract Number: 1999 • ACR Convergence 2022
Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)
Vibeke Strand¹, Emelly Rusli², Lixia Zhang², Christina Le-Short², Alix Arnaud², Johanna Withers³ and Sam Asgarian², ¹Stanford University School of Medicine, Stanford, CA, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corportaion, Waltham, MA
Background/Purpose: Rheumatoid arthritis (RA) treatment response is typically defined using clinician-reported scores and patient global assessments of disease activity (PtGA), but patients may have a…
Abstract Number: 1994 • ACR Convergence 2022
Is Glucocorticoid Bridging Associated with Later Glucocorticoid and Biological DMARD Use in Patients with Rheumatoid Arthritis?
Lotte van Ouwerkerk¹, Sytske Anne Bergstra², Tjardo Maarseveen¹, Rachel Knevel¹, Tom Huizinga¹ and CF Allaart¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands
Background/Purpose: Glucocorticoids (GC) are rapidly effective in suppressing disease activity in rheumatoid arthritis (RA), and are often used as 'bridging' therapy while slower acting conventional…
Abstract Number: 2004 • ACR Convergence 2022
Which Route and Dose of Corticosteroids Is Most Effective in Inducing Remission in Early Rheumatoid Arthritis? A Systematic Literature Review and Meta-analysis
Laura Parker¹ and Nicola Gullick², ¹University of Warwick, Coventry, United Kingdom, ²University Hospital Coventry & Warwickshire; Warwick Medical School, University of Warwick, Coventry, United Kingdom
Background/Purpose: Current NICE guidance for rheumatoid arthritis (RA) states that glucocorticoids may be used for bridging therapy and to rapidly decrease inflammation in acute flares1.…
Abstract Number: 2002 • ACR Convergence 2022
Do SMS and Email Reminders Increase the Rate of Seasonal Influenza Vaccination in RA Patients Treated with Biologics: A Nested Randomized Controlled Trial Within the ART Registry?
Raphaèle Seror¹, Gabriel Baron², Sylvie Miconnet³, Rakiba Belkhir³, Martin Soubrier⁴, pascale thevenot⁵, andre basch⁶, Marie Truchetet⁷, Pascal Claudepierre⁸, Emmanuelle Dernis⁹, Hubert Marotte¹⁰, René-Marc Flipo¹¹, Olivier Brocq¹², Jacques Morel¹³, CARINE SALLIOT¹⁴, Bruno Fautrel¹⁵, Alain Saraux¹⁶, CHARLES LESKE¹⁷, Naïma Hamamouche¹⁸, Thierry schaeverbeke¹⁹, Xavier Mariette²⁰, Adeline Ruyssen-Witrand²¹ and Philippe Ravaud²², ¹University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ²AP-HP Hôtel Dieu Hospital, Université Paris Descartes, Paris, France, ³Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, ⁴Gabriel-Montpied Hospital, Clermont-Ferrand, France, ⁵French Society of rheumatology, Paris, France, ⁶Infirmerie Protestante de Lyon, Caluire-et-Cuire, France, ⁷Bordeaux University Hospital, Bordeaux, France, ⁸Paris Est Creteil University, Creteil, France, ⁹LE MANS general hospital, LE MANS, France, ¹⁰INSERM 1059, Saint-Etienne, France, ¹¹CHU Lille, Boulogne-Billancourt, France, ¹²Rheumatology- CH Princesse Grace, Monaco, Monaco, ¹³University and CHU Montpellier, Montpellier, France, ¹⁴CHR orleans, Orleans, France, ¹⁵Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ¹⁶CHU Brest, Brest, France, ¹⁷Hospital, Cholet, France, ¹⁸e-health Services Sanoïa, Gémenos, France, ¹⁹CHU de Bordeaux, Bordeaux, France, ²⁰Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ²¹CHU de Toulouse, Toulouse, France, ²²Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: In patients treated with biologics, vaccination against influenza is recommended. However, vaccination coverage remains very low. The use of automatic digital reminders is an…
Abstract Number: 2003 • ACR Convergence 2022
Anti-rheumatic Treatment Modulates Expression of the Glycolytic Enzyme PFKFB3 in CD14+ Monocytes of Patients with Rheumatoid Arthritis, Which Contributes to Dissimilarities of the IFN Signature
Malin Erlandsson¹, Karin Andersson¹, Sofia Töyrä Silfverswärd², Rille pullerits² and Maria Bokarewa², ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: Combination of IFN-stimulated genes known as IFN signature, helps to predict disease activity and treatment response in several autoimmune diseases, including rheumatoid arthritis (RA).…
Abstract Number: 1989 • ACR Convergence 2022
Predictors of Flare in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort
Nada Alrifai¹, Mohamed Tageldin², Malavikalakshmi Attur², Nicholas Wilson², Rebecca schorr² and Tarun Sharma², ¹Allegheny Health Network, Pittsburgh, ²Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Long term use of conventional synthetic DMARDs (csDMARDs) and biologics in RA has clinical risks including infection and malignancy. Few RCTs and real-world studies…
Abstract Number: 1795 • ACR Convergence 2022
Therapeutic Strategies for Patients with Chronic Manifestations of Calcium Pyrophosphate Deposition Disease
Julien Damart¹, Silvia Sirotti², Mariano Andrès³, Edoardo Cipolletta⁴, Georgios Filippou⁵, Davide Carboni⁶, Emilio Filippucci⁷, Pilar Diez⁸, Abhishek Abhishek⁹, Augustin Latourte¹⁰, Hang-Korng Ea¹¹, Sebastien Ottaviani¹², Jean-Guillaume Letarouilly¹³, Renaud Desbarbieux¹⁴, Sahara Graf¹, Laurène Norberciak¹, Pascal Richette¹⁵ and Tristan Pascart¹⁶, ¹Hôpital Saint-Philibert, Lomme, France, ²Università degli Studi di Milano, Milano, Italy, ³Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ⁴Polytechnic University of Marche, Ancona, Italy, ⁵Rheumatology Department, Luigi Sacco University Hospital, Siena, Italy, ⁶Luigi Sacco University, Milano, Italy, ⁷Polytechnic University of Marche, Rheumatology Unit, Department of Clinical and Molecular Sciences, "Carlo Urbani" Hospital, Jesi, Italy, ⁸Alicante University, Alicante, Spain, ⁹University of Nottingham, Nottingham, United Kingdom, ¹⁰Université de Paris, Paris, France, ¹¹Lariboisière Hospital, Paris, France, ¹²Hopital Bichat-Claude Bernard, Paris, France, ¹³CHU Lille, Lille, France, ¹⁴Ch Boulogne-sur-Mer, Boulogne-sur-Mer, France, ¹⁵Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ¹⁶Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease lacks recommendations on treatment strategies. This study reports on treatment modalities used in European tertiary hospitals for the management…
Abstract Number: 1539 • ACR Convergence 2022
Gene Expression Meta-Analysis Reveals Aging and Cellular Senescence Signatures in Scleroderma-associated Interstitial Lung Disease
Monica Yang¹, Seoyeon Lee², Jessica Neely³, Marina Sirota² and Paul Wolters², ¹UCSF, SF, CA, ²UCSF, SF, ³UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by diffuse fibrosis and vasculopathy that has potential to affect nearly every organ system. Interstitial lung…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].